First Three States Opt Into Cervical, Breast Cancer Treatment Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

WASHINGTON-Three states have won approval of their plans to expand Medicaid benefits to uninsured women diagnosed through the National Breast and Cervical Cancer Early Detection Program, administered by the Centers for Disease Control and Prevention. Maryland, New Hampshire, and West Virginia were approved by the Department of Health and Human Services under the Breast and Cervical Cancer and Prevention and Treatment Act (BCCPT), which Congress enacted last year.

WASHINGTON—Three states have won approval of their plans to expand Medicaid benefits to uninsured women diagnosed through the National Breast and Cervical Cancer Early Detection Program, administered by the Centers for Disease Control and Prevention. Maryland, New Hampshire, and West Virginia were approved by the Department of Health and Human Services under the Breast and Cervical Cancer and Prevention and Treatment Act (BCCPT), which Congress enacted last year.

Articles in this issue
Adjuvant Chemo Dose Reductions Frequent in Breast Cancer
Women May Be at Greater Risk for Undertreatment of Cancer Pain
Umbilical Cord Blood in Adult Leukemia Patients
Irinotecan Results Continue to Be Encouraging in Colorectal Cancer
Irinotecan Active in Pediatric Cancers
Combined Modality Therapy Has Enhanced Activity in Locally Advanced Rectal Cancer
Ultrasound Contrast Agents Help Diagnose Prostate Cancer
Optimal Use of Irinotecan Still to be Determined
Groups Urge Federal Action Against Eclipse Cigarettes
Potential Advantages of Oral Irinotecan Defined in Phase I Studies
New Website for Cancer Pain Patients
Creative Center for Women With Cancer Adds the Performing Arts
More Precise Surrogate Markers for Clinical Response Are Needed
Rubitecan Appears Active in Advanced Pancreatic Cancer
Physicians Must Unite Against New Bureaucratic ‘Hassles’ to Practicing Medicine
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
August 14th 2025
Article

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
August 12th 2025
Article

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Enhances DCIS Risk Stratification Beyond Clincopathology

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Ariana Pelosci
July 29th 2025
Article

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.